Abstract
Background
Hemolytic uremic syndrome (HUS) is a main cause of acute renal failure in children. This study aimed to analyze the clinical characteristics of HUS.
Methods
A retrospective analysis was performed in 46 children with sporadic HUS.
Results
Of the 46 HUS patients, 20 (43.5%) were diarrhea-related HUS, and 26 (56.5%) were atypical HUS. Anemia, edema, oliguria, hemoglobinuria and hypertension were the most common manifestations. Thrombocytopenia, hyponatremia, hypocalcemia, hyperkalemia, metabolic acidosis, increased fibrinogen and hypocomplementemia were found in most patients. The age of onset (younger than 2 years or not, P=0.009), the duration of oliguria or anuria (more than one week or not, P=0.005), accompanied with extrarenal complications or not (P=0.005), dialysis and plasma exchange (P=0.04) were associated with the mortality rate.
Conclusions
The age of onset younger than 2 years, oliguria/anuria more than 1 week, and associated with extrarenal complications were predictive factors of poor prognosis.
Similar content being viewed by others
References
Tserenpuntsag B, Chang HG, Smith PF, Morse DL. Hemolytic uremic syndrome risk and Escherichia coli O157:H7. Emerg Infect Dis 2005;11:1955–1957.
Rock G, Kolajova M, Faught C, Zimmerman D. Identification of plasma antifibrin/fibrinogen antibodies in a patient with hemolytic uremic syndrome. Blood Coagul Fibrinolysis 2006;17:539–544.
Zhang Y, Meng Q, Zhou C. The epidemic survey of children with hemolytic uremic syndrome (HUS), analysis of the death patients and therapeutic advance in 35 years in Beijing Children’s Hospital. J Clin Pediatr (Chinese) 2003;21:545–548. [In Chinese]
Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-Durey MA, et al. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). Methods Mol Biol 2014;1100:237–247.
Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 2016;68:84–93.
Nakatani T, Tsuchida K, Yoshimura R, Sugimura K, Takemoto Y. Plasma exchange therapy for the treatment of Escherichia coli O-157 associated hemolytic uremic syndrome. Int J Mol Med 2002;10:585–588.
Slavicek J, Puretic Z, Novak M, Sarnavka V, Benjak V, Glavas-Boras S, et al. The role of plasma exchange in the treatment of severe forms of hemolytic-uremic syndrome in childhood. Artif Organs 1995;19:506–510.
Cobenas CJ, Alconcher LF, Spizzirri AP, Rahman RC. Longterm follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis. Pediatr Nephrol 2007;22:1343–1347.
Bhimma R, Coovadia HM, Adhikari M, Connolly CA. Reevaluating criteria for peritoneal dialysis in "classical" (D+) hemolytic uremic syndrome. Clin Nephrol 2001;55:133–142.
Mody RK, Gu W, Griffin PM, Jones TF, Rounds J, Shiferaw B, et al. Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 2015;166:1022–1029.
Kawasaki Y, Suyama K, Maeda R, Yugeta E, Takano K, Suzuki S, et al. Incidence and index of severity of hemolytic uremic syndrome in a 26 year period in Fukushima Prefecture, Japan. Pediatr Int 2014;56:77–82.
Gianviti A, Tozzi AE, De Petris L, Caprioli A, Rava L, Edefonti A, et al. Risk factors for poor renal prognosis in children with hemolytic uremic syndrome. Pediatr Nephrol 2003;18:1229–1235.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhao, SA., Ning, BT. & Mao, JH. Clinical characteristics of children with hemolytic uremic syndrome in Hangzhou, China. World J Pediatr 13, 183–185 (2017). https://doi.org/10.1007/s12519-017-0021-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-017-0021-x